Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Bad bug, no test: Tigecycline susceptibility testing challenges and way forward.

Shankar C, Pragasam AK, Veeraraghavan B, Amladi A.

Indian J Med Microbiol. 2019 Jan-Mar;37(1):91-94. doi: 10.4103/ijmm.IJMM_19_207.

PMID:
31424015
2.

Colistin-sparing approaches with newer antimicrobials to treat carbapenem-resistant organisms: Current evidence and future prospects.

Veeraraghavan B, Pragasam AK, Bakthavatchalam YD, Anandan S, Swaminathan S, Sundaram B.

Indian J Med Microbiol. 2019 Jan-Mar;37(1):72-90. doi: 10.4103/ijmm.IJMM_19_215. Review.

PMID:
31424014
3.

Microbiological profile and outcomes of two-stage revision hip arthroplasty.

Hariharan TD, Chandy VJ, George J, Mathew AJ, Premnath J, Pragasam AK, Prakash JJ, Oomen AT, Poonnoose PM.

Indian J Med Microbiol. 2019 Jan-Mar;37(1):67-71. doi: 10.4103/ijmm.IJMM_19_25.

PMID:
31424013
4.

Will ceftazidime/avibactam plus aztreonam be effective for NDM and OXA-48-Like producing organisms: Lessons learnt from In vitro study.

Pragasam AK, Veeraraghavan B, Shankar BA, Bakthavatchalam YD, Mathuram A, George B, Chacko B, Korula P, Anandan S.

Indian J Med Microbiol. 2019 Jan-Mar;37(1):34-41. doi: 10.4103/ijmm.IJMM_19_189.

PMID:
31424008
5.

Rapidly disseminating blaOXA-232 carrying Klebsiella pneumoniae belonging to ST231 in India: multiple and varied mobile genetic elements.

Shankar C, Mathur P, Venkatesan M, Pragasam AK, Anandan S, Khurana S, Veeraraghavan B.

BMC Microbiol. 2019 Jun 24;19(1):137. doi: 10.1186/s12866-019-1513-8.

6.

Plasmid profiles among some ESKAPE pathogens in a tertiary care centre in south India.

Ragupathi NKD, Bakthavatchalam YD, Mathur P, Pragasam AK, Walia K, Ohri VC, Veeraraghavan B.

Indian J Med Res. 2019 Feb;149(2):222-231. doi: 10.4103/ijmr.IJMR_2098_17.

7.

Molecular characterization of colistin-resistant Klebsiella pneumoniae & its clonal relationship among Indian isolates.

Shankar C, Venkatesan M, Rajan R, Mani D, Lal B, Prakash JAJ, Anandan S, Pragasam AK, Walia K, Ohri VC, Veeraraghavan B.

Indian J Med Res. 2019 Feb;149(2):199-207. doi: 10.4103/ijmr.IJMR_2087_17.

8.

Genomic analysis of human invasive Salmonella enterica serovar Typhimurium ST313 isolate B3589 from India.

Jacob JJ, Anandan S, Venkatesan M, Neeravi A, Vasudevan K, Pragasam AK, Veeraraghavan B.

Infect Genet Evol. 2019 Jun 3;73:416-424. doi: 10.1016/j.meegid.2019.05.023. [Epub ahead of print]

PMID:
31170530
9.

mgrB as Hotspot for Insertion Sequence Integration: Change Over from Multidrug-Resistant to Extensively Drug-Resistant Klebsiella pneumoniae?

Shankar C, Pragasam AK, Anandan S, Veeraraghavan B.

Microb Drug Resist. 2019 Apr 4. doi: 10.1089/mdr.2018.0415. [Epub ahead of print] No abstract available.

PMID:
30946628
10.

Risk factors and epidemiologic predictors of blood stream infections with New Delhi Metallo-b-lactamase (NDM-1) producing Enterobacteriaceae.

Snyder BM, Montague BT, Anandan S, Madabhushi AG, Pragasam AK, Verghese VP, Balaji V, Simões EAF.

Epidemiol Infect. 2019 Jan;147:e137. doi: 10.1017/S0950268819000256.

11.

Antimicrobial Susceptibility Testing Methods for Acinetobacter spp.

Veeraraghavan B, Vijayakumar S, Pragasam AK, Bakthavachalam YD, Prakash JAJ.

Methods Mol Biol. 2019;1946:23-37. doi: 10.1007/978-1-4939-9118-1_3.

PMID:
30798541
12.

Genotyping of Acinetobacter baumannii in Nosocomial Outbreak and Surveillance.

Vijayakumar S, Veeraraghavan B, Pragasam AK, Bakthavachalam YD.

Methods Mol Biol. 2019;1946:17-22. doi: 10.1007/978-1-4939-9118-1_2.

PMID:
30798540
13.

Efficacy ratio: A tool to enhance optimal antimicrobial use for intra-abdominal infections.

Sabu P, Elangovan D, Pragasam AK, Bakthavatchalam YD, Rodrigues C, Chitnis DS, Chaudhuri BN, Veeraraghavan B.

Indian J Pharmacol. 2018 Nov-Dec;50(6):332-335. doi: 10.4103/ijp.IJP_264_18.

14.

Extensive drug resistant Salmonella enterica serovar Senftenberg carrying blaNDM encoding plasmid p5558 (IncA/C) from India.

Veeraraghavan B, Jacob JJ, Prakash JAJ, Pragasam AK, Neeravi A, Narasimman V, Anandan S.

Pathog Glob Health. 2019 Feb;113(1):20-26. doi: 10.1080/20477724.2019.1574112. Epub 2019 Feb 6.

PMID:
30722761
15.

Dominance of international high-risk clones in carbapenemase-producing Pseudomonas aeruginosa: Multicentric molecular epidemiology report from India.

Pragasam AK, Veeraraghavan B, Anandan S, Narasiman V, Sistla S, Kapil A, Mathur P, Ray P, Wattal C, Bhattacharya S, Deotale V, Subramani K, Peter JV, Hariharan TD, Ramya I, Iniyan S, Walia K, Ohri VC.

Indian J Med Microbiol. 2018 Jul-Sep;36(3):344-351. doi: 10.4103/ijmm.IJMM_18_294.

16.

Newer β-Lactam/β-Lactamase inhibitor for multidrug-resistant gram-negative infections: Challenges, implications and surveillance strategy for India.

Veeraraghavan B, Pragasam AK, Bakthavatchalam YD, Anandan S, Ramasubramanian V, Swaminathan S, Gopalakrishnan R, Soman R, Abraham OC, Ohri VC, Walia K.

Indian J Med Microbiol. 2018 Jul-Sep;36(3):334-343. doi: 10.4103/ijmm.IJMM_18_326. Review.

17.

An update on antimicrobial resistance and the role of newer antimicrobial agents for Pseudomonas aeruginosa.

Pragasam AK, Veeraraghavan B, Nalini E, Anandan S, Kaye KS.

Indian J Med Microbiol. 2018 Jul-Sep;36(3):303-316. doi: 10.4103/ijmm.IJMM_18_334. Review.

18.

Typhoid fever: issues in laboratory detection, treatment options & concerns in management in developing countries.

Veeraraghavan B, Pragasam AK, Bakthavatchalam YD, Ralph R.

Future Sci OA. 2018 Jun 26;4(6):FSO312. doi: 10.4155/fsoa-2018-0003. eCollection 2018 Jul. Review.

19.

Longitudinal Typhoid Fever Trends in India from 2000 to 2015.

Balaji V, Kapil A, Shastri J, Pragasam AK, Gole G, Choudhari S, Kang G, John J.

Am J Trop Med Hyg. 2018 Sep;99(3_Suppl):34-40. doi: 10.4269/ajtmh.18-0139. Epub 2018 Jul 24.

20.

Antimicrobial susceptibility profiles of gram-negative bacteria causing infections collected across India during 2014-2016: Study for monitoring antimicrobial resistance trend report.

Veeraraghavan B, Jesudason MR, Prakasah JAJ, Anandan S, Sahni RD, Pragasam AK, Bakthavatchalam YD, Selvakumar RJ, Dhole TN, Rodrigues C, Roy I, Joshi S, Chaudhuri BN, Chitnis DS.

Indian J Med Microbiol. 2018 Jan-Mar;36(1):32-36. doi: 10.4103/ijmm.IJMM_17_415.

21.

Dosing strategy based on prevailing aminoglycoside minimum inhibitory concentration in India: Evidence and issues.

Veeraraghavan B, Pragasam AK, Manesh A, Rupali P, Iyadurai R, Rodrigues C, Joshi S, Roy I, Chaudhuri BN, Chitnis DS, Tapan D.

Indian J Med Microbiol. 2017 Oct-Dec;35(4):585-587. doi: 10.4103/ijmm.IJMM_17_386.

22.

An update on technical, interpretative and clinical relevance of antimicrobial synergy testing methodologies.

Laishram S, Pragasam AK, Bakthavatchalam YD, Veeraraghavan B.

Indian J Med Microbiol. 2017 Oct-Dec;35(4):445-468. doi: 10.4103/ijmm.IJMM_17_189. Review.

23.

Polymyxin susceptibility testing, interpretative breakpoints and resistance mechanisms: An update.

Bakthavatchalam YD, Pragasam AK, Biswas I, Veeraraghavan B.

J Glob Antimicrob Resist. 2018 Mar;12:124-136. doi: 10.1016/j.jgar.2017.09.011. Epub 2017 Sep 28. Review.

PMID:
28962863
24.

Strengths and limitations of various screening methods for carbapenem-resistant Enterobacteriaceae including new method recommended by clinical and laboratory standards institute, 2017: A tertiary care experience.

Pragasam AK, Veeraraghavan B, Bakthavatchalam YD, Gopi R, Aslam RF.

Indian J Med Microbiol. 2017 Jan-Mar;35(1):116-119. doi: 10.4103/ijmm.IJMM_17_10.

25.

Characterisation of antimicrobial resistance in Salmonellae during 2014-2015 from four centres across India: An ICMR antimicrobial resistance surveillance network report.

Dahiya S, Sharma P, Kumari B, Pandey S, Malik R, Manral N, Veeraraghavan B, Pragasam AK, Ray P, Gautam V, Sistla S, Parija SC, Walia K, Ohri V, Das BK, Sood S, Kapil A.

Indian J Med Microbiol. 2017 Jan-Mar;35(1):61-68. doi: 10.4103/ijmm.IJMM_16_382.

26.

Molecular Mechanisms of Colistin Resistance in Klebsiella pneumoniae Causing Bacteremia from India-A First Report.

Pragasam AK, Shankar C, Veeraraghavan B, Biswas I, Nabarro LE, Inbanathan FY, George B, Verghese S.

Front Microbiol. 2017 Jan 9;7:2135. doi: 10.3389/fmicb.2016.02135. eCollection 2016.

27.

Clinical and Bacterial Risk Factors for Mortality in Children With Carbapenem-resistant Enterobacteriaceae Bloodstream Infections in India.

Nabarro LEB, Shankar C, Pragasam AK, Mathew G, Jeyaseelan V, Veeraraghavan B, Verghese VP.

Pediatr Infect Dis J. 2017 Jun;36(6):e161-e166. doi: 10.1097/INF.0000000000001499.

PMID:
28005691
28.

Molecular characterisation of antimicrobial resistance in Pseudomonas aeruginosa and Acinetobacter baumannii during 2014 and 2015 collected across India.

Pragasam AK, Vijayakumar S, Bakthavatchalam YD, Kapil A, Das BK, Ray P, Gautam V, Sistla S, Parija SC, Walia K, Ohri VC, Anandan S, Veeraraghavan B.

Indian J Med Microbiol. 2016 Oct-Dec;34(4):433-441. doi: 10.4103/0255-0857.195376.

29.

Coexistence of Fosfomycin and Colistin Resistance in Klebsiella pneumoniae: Whole-Genome Shotgun Sequencing.

Veeraraghavan B, Perumalla SK, Devanga Ragupathi NK, Pragasam AK, Muthuirulandi Sethuvel DP, Inian S, Inbanathan FY.

Genome Announc. 2016 Nov 23;4(6). pii: e01303-16. doi: 10.1128/genomeA.01303-16.

30.

Whole-Genome Shotgun Sequencing of the First Observation of Neisseria meningitidis Sequence Type 6928 in India.

Veeraraghavan B, Neeravi AR, Devanga Ragupathi NK, Inbanathan FY, Pragasam AK, Verghese VP.

Genome Announc. 2016 Nov 3;4(6). pii: e01232-16. doi: 10.1128/genomeA.01232-16.

31.

Draft Genome Sequence of Extremely Drug-Resistant Pseudomonas aeruginosa (ST357) Strain CMC_VB_PA_B22862 Isolated from a Community-Acquired Bloodstream Infection.

Pragasam AK, Yesurajan F, Doss C GP, George B, Devanga Ragupathi NK, Walia K, Veeraraghavan B.

Genome Announc. 2016 Oct 20;4(5). pii: e01092-16. doi: 10.1128/genomeA.01092-16.

32.

A Pilot Study on Carbapenemase Detection: Do We See the Same Level of Agreement as with the CLSI Observations.

Pragasam AK, Sahni RD, Anandan S, Sharma A, Gopi R, Hadibasha N, Gunasekaran P, Veeraraghavan B.

J Clin Diagn Res. 2016 Jul;10(7):DC09-13. doi: 10.7860/JCDR/2016/16417.8152. Epub 2016 Jul 1.

33.

Characterization of Pseudomonas aeruginosa with discrepant carbapenem susceptibility profile.

Pragasam AK, Raghanivedha M, Anandan S, Veeraraghavan B.

Ann Clin Microbiol Antimicrob. 2016 Feb 24;15:12. doi: 10.1186/s12941-016-0127-3.

34.

Comparative in-vitro activity of ceftaroline against Staphylococcus aureus isolates from India.

Bakthavatchalam YD, Pragasam AK, Anandan S, Joshi S, Chaudhuri BN, Chitnis DS, Roy I, Tapan D, Veeraraghavan B.

J Infect Dev Ctries. 2016 Jan 31;10(1):109-12. doi: 10.3855/jidc.7196. No abstract available.

35.

Molecular Characterization of Imipenem-Resistant, Meropenem-Susceptible Pseudomonas aeruginosa with blaVIM₋₂ Phenotype: Potential for Dissemination.

Pragasam AK, Raghanivedha M, Anandan S, Veeraraghavan B.

Jpn J Infect Dis. 2016;69(2):159-60. doi: 10.7883/yoken.JJID.2015.273. Epub 2015 Nov 13. No abstract available.

36.

Antimicrobial susceptibility profile of isolates from pediatric blood stream infections.

Rose W, Veeraraghavan B, Pragasam AK, Verghese VP.

Indian Pediatr. 2014 Sep;51(9):752-3.

Supplemental Content

Loading ...
Support Center